IRB #

STUDY00022463

Title

[NCI CIRB] A021804 - A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Principal Investigator

Michael Heinrich

Study Purpose

This study is being done to find out if we can lower the chance of your pheochromocytoma or paraganglioma from growing or spreading by comparing two treatments of olaparib plus temozolomide vs. temozolomide. Also, we hope to find out if this approach is better or worse than the usual approach.

Medical Condition(s)

Pheochromocytoma and Paraganglioma

Eligibility Criteria

Histologically proven advanced pheochromocytoma or paraganglioma

Prior treatment with other chemotherapy, radiotherapy, or surgery must be completed >28 days prior to registration.

Prior treatment with radiolabeled MIBG must be completed >12 weeks prior to registration.

Prior treatment with antibiotics must be completed >7 days prior to registration.

No prior treatment with temozolomide, dacarbazine, or a poly ADP ribose polymerase (PARP) inhibitor.

No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation.

>18 years of age

Performance status of 0-2

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

5 years

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

Alliance

Recruitment End

01/02/2023

Compensation Provided

No


Go Back